[{"id":"b44521d2-5829-4bf3-b6c2-ad08cfcaf642","acronym":"","url":"https://clinicaltrials.gov/study/NCT06863805","created_at":"2025-07-19T14:06:15.287Z","updated_at":"2025-07-19T14:06:15.287Z","phase":"","brief_title":"Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas","source_id_and_acronym":"NCT06863805","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" BRAF • ALK • RET • RAS • NTRK","pipe":" | ","alterations":" RAS mutation • RET mutation","tags":["BRAF • ALK • RET • RAS • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation • RET mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-03-07"},{"id":"ae6dde76-a9e2-4ffe-85b4-d60ff795f82d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03919292","created_at":"2021-01-18T19:17:11.532Z","updated_at":"2025-02-25T13:48:40.499Z","phase":"Phase 1/2","brief_title":"Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca","source_id_and_acronym":"NCT03919292","lead_sponsor":"Virginia Commonwealth University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • RAS mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-21"},{"id":"9746c38a-e183-480a-bcc4-ea83361a9977","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554328","created_at":"2022-09-26T14:56:09.383Z","updated_at":"2025-02-25T13:49:33.072Z","phase":"Phase 2","brief_title":"Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554328","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation","tags":["KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Koselugo (selumetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 04/25/2023","start_date":" 04/25/2023","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2025-02-20"},{"id":"5325032a-dfb5-4381-8e59-f5e1418ec3ae","acronym":"DASH","url":"https://clinicaltrials.gov/study/NCT04704661","created_at":"2021-01-19T20:51:17.334Z","updated_at":"2025-02-25T14:02:10.901Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","source_id_and_acronym":"NCT04704661 - DASH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53 • ATM • RAS • CD4","pipe":" | ","alterations":" HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation","tags":["HER-2 • TP53 • ATM • RAS • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-19"},{"id":"bb866355-1e34-4d35-9bb4-a41598c5e17e","acronym":"IMM1104-101","url":"https://clinicaltrials.gov/study/NCT05585320","created_at":"2022-10-18T14:57:21.622Z","updated_at":"2025-02-25T14:09:12.843Z","phase":"Phase 1/2","brief_title":"A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05585320 - IMM1104-101","lead_sponsor":"Immuneering Corporation","biomarkers":" KRAS • HRAS • APC","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation","tags":["KRAS • HRAS • APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • atebimetinib (IMM-1-104)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 10/31/2022","start_date":" 10/31/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-19"},{"id":"1858e4d9-b3bc-4f84-941b-cd90075ac7b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708054","created_at":"2021-01-19T20:51:54.886Z","updated_at":"2025-02-25T14:08:06.998Z","phase":"Phase 2","brief_title":"Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS","source_id_and_acronym":"NCT04708054","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • NRAS • DNMT3A • NF1 • RUNX1 • ASXL1 • PTPN1","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • NRAS mutation • RAS mutation","tags":["KRAS • NRAS • DNMT3A • NF1 • RUNX1 • ASXL1 • PTPN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cladribine • fludarabine IV • thiotepa • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-18"},{"id":"6553092f-70e4-434d-af85-c9de431dfb02","acronym":"","url":"https://clinicaltrials.gov/study/NCT03290937","created_at":"2021-01-18T16:15:28.855Z","updated_at":"2025-02-25T14:07:03.272Z","phase":"Phase 1","brief_title":"Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03290937","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR • RAS mutation","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • irinotecan • utomilumab (PF-05082566) • Datalai (cetuximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-17"},{"id":"a5794ed7-ec20-4c8e-af55-9e059e2c03e3","acronym":"RASolute 302","url":"https://clinicaltrials.gov/study/NCT06625320","created_at":"2025-02-25T14:19:38.953Z","updated_at":"2025-02-25T14:19:38.953Z","phase":"Phase 3","brief_title":"Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","source_id_and_acronym":"NCT06625320 - RASolute 302","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" RAS","pipe":" | ","alterations":" RAS mutation","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • daraxonrasib (RMC-6236)"],"overall_status":"Recruiting","enrollment":" Enrollment 460","initiation":"Initiation: 10/16/2024","start_date":" 10/16/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-17"},{"id":"de85007a-8a96-4d92-b410-2aebe8f02c18","acronym":"","url":"https://clinicaltrials.gov/study/NCT06007924","created_at":"2023-08-23T15:11:08.435Z","updated_at":"2025-02-25T15:13:43.406Z","phase":"Phase 2","brief_title":"A Study of Avutometinib and Defactinib in People With Thyroid Cancer","source_id_and_acronym":"NCT06007924","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • ALK • RET • NF1 • NTRK","pipe":" | ","alterations":" BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement","tags":["BRAF • ALK • RET • NF1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/16/2023","start_date":" 08/16/2023","primary_txt":" Primary completion: 08/16/2027","primary_completion_date":" 08/16/2027","study_txt":" Completion: 08/16/2027","study_completion_date":" 08/16/2027","last_update_posted":"2025-02-13"},{"id":"23df8c55-37d1-4d81-9a8c-51e5c6811bf0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03983850","created_at":"2021-01-18T19:35:37.156Z","updated_at":"2025-02-25T15:26:05.857Z","phase":"Phase 1/2","brief_title":"Optimizing PTCy Dose and Timing","source_id_and_acronym":"NCT03983850","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • PTEN • IGH • FBXW7","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS • PTEN • IGH • FBXW7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 07/09/2019","start_date":" 07/09/2019","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/29/2026","study_completion_date":" 05/29/2026","last_update_posted":"2025-02-11"},{"id":"6e8c9c85-9d26-4c35-8860-c80648e49b52","acronym":"","url":"https://clinicaltrials.gov/study/NCT02188264","created_at":"2021-01-18T10:12:45.005Z","updated_at":"2025-02-25T15:25:18.307Z","phase":"Phase 1","brief_title":"Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02188264","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • RAF1 • MAPK1","pipe":" | ","alterations":" BRAF mutation • RAS mutation","tags":["BRAF • RAF1 • MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib) • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 08/29/2014","start_date":" 08/29/2014","primary_txt":" Primary completion: 01/31/2017","primary_completion_date":" 01/31/2017","study_txt":" Completion: 04/26/2019","study_completion_date":" 04/26/2019","last_update_posted":"2025-02-11"},{"id":"b830c833-61a0-434d-8a29-24074697ffb9","acronym":"DURAFAK","url":"https://clinicaltrials.gov/study/NCT05512208","created_at":"2022-08-23T14:55:32.872Z","updated_at":"2025-02-25T15:27:34.112Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib","source_id_and_acronym":"NCT05512208 - DURAFAK","lead_sponsor":"University of Oklahoma","biomarkers":" BRAF • NF1 • RAS","pipe":" | ","alterations":" BRAF mutation • RAS mutation","tags":["BRAF • NF1 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 02/06/2023","start_date":" 02/06/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-02-10"},{"id":"92c099b7-baf6-420f-bbb6-7c2961993e03","acronym":"","url":"https://clinicaltrials.gov/study/NCT05674526","created_at":"2023-01-06T15:58:52.282Z","updated_at":"2025-02-25T16:39:35.039Z","phase":"Phase 1","brief_title":"A Phase 1b Study of WU-NK-101 in Combination With Cetuximab","source_id_and_acronym":"NCT05674526","lead_sponsor":"Wugen, Inc.","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • EGFR expression • RAS mutation","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • EGFR expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • WU-NK-101"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/21/2024","start_date":" 05/21/2024","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-07"},{"id":"29c59c3c-4af3-4d3c-bbe9-82bcfe995e5f","acronym":"CAIRO5","url":"https://clinicaltrials.gov/study/NCT02162563","created_at":"2021-01-18T10:04:04.928Z","updated_at":"2025-02-25T16:36:23.493Z","phase":"Phase 3","brief_title":"Treatment Strategies in Colorectal Cancer Patients with Initially Unresectable Liver-only Metastases","source_id_and_acronym":"NCT02162563 - CAIRO5","lead_sponsor":"Dutch Colorectal Cancer Group","biomarkers":" BRAF • RAS","pipe":" | ","alterations":" BRAF mutation • RAS mutation","tags":["BRAF • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 530","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 07/01/2022","primary_completion_date":" 07/01/2022","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2025-02-06"},{"id":"7218af24-4289-464c-b642-c450f941d6b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01814501","created_at":"2021-01-18T08:03:17.318Z","updated_at":"2025-02-25T16:43:42.557Z","phase":"Phase 2","brief_title":"Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab","source_id_and_acronym":"NCT01814501","lead_sponsor":"John Hays","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • RAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 08/06/2018","primary_completion_date":" 08/06/2018","study_txt":" Completion: 08/06/2018","study_completion_date":" 08/06/2018","last_update_posted":"2025-02-05"},{"id":"7460cc37-d435-44b0-a888-a97d57a2e6c3","acronym":"START-001","url":"https://clinicaltrials.gov/study/NCT05592626","created_at":"2022-10-24T13:57:11.728Z","updated_at":"2025-02-25T17:31:39.938Z","phase":"Phase 1/2","brief_title":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors","source_id_and_acronym":"NCT05592626 - START-001","lead_sponsor":"Marengo Therapeutics, Inc.","biomarkers":" KRAS • TMB • MSI • RAS","pipe":" | ","alterations":" KRAS mutation • TMB-H • MSI-H/dMMR • RAS mutation • RAS wild-type","tags":["KRAS • TMB • MSI • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • TMB-H • MSI-H/dMMR • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e invikafusp alfa (STAR0602)"],"overall_status":"Recruiting","enrollment":" Enrollment 365","initiation":"Initiation: 01/04/2023","start_date":" 01/04/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-01-30"},{"id":"c140a8b8-ac68-4df9-988d-ebe6e54e87b6","acronym":"DETERMINE","url":"https://clinicaltrials.gov/study/NCT06194929","created_at":"2024-01-08T19:20:11.355Z","updated_at":"2025-02-25T17:32:44.459Z","phase":"Phase 1/2","brief_title":"Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma","source_id_and_acronym":"NCT06194929 - DETERMINE","lead_sponsor":"University of Utah","biomarkers":" NF1 • RAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation","tags":["NF1 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Braftovi (encorafenib) • Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 03/07/2024","start_date":" 03/07/2024","primary_txt":" Primary completion: 01/15/2028","primary_completion_date":" 01/15/2028","study_txt":" Completion: 01/15/2030","study_completion_date":" 01/15/2030","last_update_posted":"2025-01-30"},{"id":"9ef28cb0-6b0e-4242-8ea3-6de25a48faed","acronym":"LEAP-008","url":"https://clinicaltrials.gov/study/NCT03976375","created_at":"2021-01-18T19:33:26.274Z","updated_at":"2025-02-25T13:35:24.264Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)","source_id_and_acronym":"NCT03976375 - LEAP-008","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • KRAS • ALK • ROS1","pipe":" | ","alterations":" KRAS mutation • EGFR L858R • ALK rearrangement • RAS mutation","tags":["EGFR • KRAS • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR L858R • ALK rearrangement • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 422","initiation":"Initiation: 06/26/2019","start_date":" 06/26/2019","primary_txt":" Primary completion: 08/11/2023","primary_completion_date":" 08/11/2023","study_txt":" Completion: 08/22/2024","study_completion_date":" 08/22/2024","last_update_posted":"2024-11-18"},{"id":"a0cf279a-8d5c-46c3-9bca-6f57de2820c1","acronym":"NAUTICALCRC","url":"https://clinicaltrials.gov/study/NCT05004350","created_at":"2021-08-13T12:53:27.664Z","updated_at":"2025-02-25T16:16:36.860Z","phase":"Phase 2","brief_title":"A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.","source_id_and_acronym":"NCT05004350 - NAUTICALCRC","lead_sponsor":"Pierre Fabre Medicament","biomarkers":" BRAF • MSI • CEACAM5 • RAF1 • RAS • CA 19-9","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • RAS mutation • RAS wild-type","tags":["BRAF • MSI • CEACAM5 • RAF1 • RAS • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • Braftovi (encorafenib) • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 12/19/2023","primary_completion_date":" 12/19/2023","study_txt":" Completion: 01/11/2025","study_completion_date":" 01/11/2025","last_update_posted":"2024-06-18"},{"id":"f7f0dd30-c5fe-4b5b-bd30-831480836846","acronym":"ARMANI","url":"https://clinicaltrials.gov/study/NCT04678583","created_at":"2021-01-19T20:46:12.268Z","updated_at":"2024-07-02T16:34:26.543Z","phase":"","brief_title":"Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer","source_id_and_acronym":"NCT04678583 - ARMANI","lead_sponsor":"Technische Universität Dresden","biomarkers":" KRAS • NRAS • RAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • RAS mutation","tags":["KRAS • NRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • RAS mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-06-13"},{"id":"1251a894-93e6-4c49-a11d-e5400df1cba5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05605509","created_at":"2022-11-04T16:58:13.524Z","updated_at":"2024-07-02T16:34:26.676Z","phase":"Phase 2","brief_title":"RP-6306 in Patients With Advanced Cancer","source_id_and_acronym":"NCT05605509","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2 • KRAS • TP53 • CCNE1 • UGT1A1","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation • CCNE1 amplification • UGT1A1*28 • UGT1A1*1*1","tags":["HER-2 • KRAS • TP53 • CCNE1 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation • CCNE1 amplification • UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • gemcitabine • 5-fluorouracil • irinotecan • leucovorin calcium • lunresertib (RP-6306)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 05/24/2023","start_date":" 05/24/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-12"},{"id":"a3759a52-c4d8-4024-b32b-cdbe20861361","acronym":"","url":"https://clinicaltrials.gov/study/NCT05239741","created_at":"2022-02-15T16:53:10.993Z","updated_at":"2024-07-02T16:35:00.681Z","phase":"Phase 3","brief_title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","source_id_and_acronym":"NCT05239741","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" BRAF • MSI • RAS","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation • RAS mutation • RAS wild-type","tags":["BRAF • MSI • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/02/2022","start_date":" 04/02/2022","primary_txt":" Primary completion: 11/10/2026","primary_completion_date":" 11/10/2026","study_txt":" Completion: 11/10/2026","study_completion_date":" 11/10/2026","last_update_posted":"2024-05-27"},{"id":"02eaf617-0513-44fc-bea7-b3c0c01ecd8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05849662","created_at":"2023-05-09T14:04:18.433Z","updated_at":"2024-07-02T16:35:02.520Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia","source_id_and_acronym":"NCT05849662","lead_sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","biomarkers":" KRAS • NRAS • NF1 • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation","tags":["KRAS • NRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • cytarabine • azacitidine • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 05/10/2024","start_date":" 05/10/2024","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-05-20"},{"id":"73b3aa11-82e5-4734-9422-2ec9801b0340","acronym":"RGX-202-001","url":"https://clinicaltrials.gov/study/NCT03597581","created_at":"2021-01-17T18:03:39.860Z","updated_at":"2024-07-02T16:35:03.556Z","phase":"Phase 1","brief_title":"A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer","source_id_and_acronym":"NCT03597581 - RGX-202-001","lead_sponsor":"Inspirna, Inc.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR • RAS mutation","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • ompenaclid (RGX-202)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 06/05/2018","start_date":" 06/05/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-15"}]